C ombination A TR (ceralasertib) and P A R P (olaparib) I nhibitor (CAPRI) Trial in Acquired PARP Inhibitor–Resistant Homologous Recombination–Deficient Ovarian Cancer

Stephanie L. Wethington; Payal D. Shah; Lainie P. Martin; János L. Tanyi; Nawar Latif; Mark A. Morgan; Drew A. Torigian; Diego Rodriguez; Simon A. Smith; Emma Dean; Susan M. Domchek; Ronny Drapkin; Ie−Ming Shih; Eric J. Brown; Wei‐Ting Hwang; Deborah K. Armstrong; Stéphanie Gaillard; Robert Giuntoli; Fiona Simpkins

doi:10.1158/1078-0432.ccr-22-2444

Abstract

Combination olaparib and ceralasertib is tolerable and shows activity in HR-deficient platinum-sensitive recurrent HGSOC that benefited and then progressed with PARPi as the penultimate regimen. These data suggest that ceralasertib resensitizes PARPi-resistant HGSOCs to olaparib, warranting further investigation.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Wethington et al. (2023) studied this question.

synapsesocial.com/papers/69dd1d19854f360ad6359aad https://doi.org/10.1158/1078-0432.ccr-22-2444

View Full Paper

Ask AI

Bookmark

Share

C ombination A TR (ceralasertib) and P A R P (olaparib) I nhibitor (CAPRI) Trial in Acquired PARP Inhibitor–Resistant Homologous Recombination–Deficient Ovarian Cancer

Abstract

Discussion

Cite This Study

C ombination A TR (ceralasertib) and P A R P (olaparib) I nhibitor (CAPRI) Trial in Acquired PARP Inhibitor–Resistant Homologous Recombination–Deficient Ovarian Cancer

Abstract

Discussion

Cite This Study

Keep reading

Keep reading